|Efavirenz||Non-nucleoside reverse transcriptase inhibitor|
|Lamivudine||Nucleoside reverse transcriptase inhibitor|
|Tenofovir||Nucleoside reverse transcriptase inhibitor|
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed dose combination medication for the treatment of HIV/AIDS. It combines efavirenz, lamivudine, and tenofovir. As of 2010 it is a first line option in the developing world. It is taken by mouth.
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. Severe side effects may include depression, psychosis, or osteonecrosis. In those with a history of epilepsy, it may increase the frequency of seizures. Greater care should also be taken in those with kidney problems. It is unclear if use during pregnancy is safe.
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. A year of medication is estimated to costs 154 USD in the developing world as of 2011. The combination received tentative approval in the United States in 2014. Its availability and importance is supported by Medecins Sans Frontieres.
- "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
- "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.
- "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017.
- "Efavirenz/lamivudine/tenofovir disoproxil fumarate fixed-dose combination tablets (600/300/300 mg FDC)" (PDF). WHO. p. 17.